Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Iclusig ponatinib: Phase III started

December 14, 2015 8:00 AM UTC

Ariad began the open-label, international Phase III OPTIC-2L trial to compare 15 and 30 mg oral Iclusig once daily vs. oral Tasigna nilotinib twice daily in about 600 patients who are resistant to G...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article